Gregory Renza
Stock Analyst at Truist Securities
(4.05)
# 281
Out of 5,178 analysts
255
Total ratings
38.89%
Success rate
16.59%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines AG | Maintains: Buy | $400 → $412 | $276.95 | +48.76% | 4 | Feb 27, 2026 | |
| GILD Gilead Sciences | Maintains: Buy | $145 → $152 | $136.88 | +11.05% | 3 | Feb 11, 2026 | |
| CGON CG Oncology | Maintains: Buy | $66 → $75 | $66.67 | +12.49% | 6 | Feb 10, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $820 → $818 | $756.73 | +8.10% | 3 | Feb 2, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $41 → $40 | $28.20 | +41.84% | 13 | Jan 8, 2026 | |
| AMGN Amgen | Maintains: Hold | $318 → $319 | $353.16 | -9.67% | 19 | Jan 8, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $59 → $60 | $32.09 | +86.97% | 14 | Jan 6, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $32 → $38 | $29.95 | +26.88% | 8 | Dec 24, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Buy | $14 → $18 | $6.94 | +159.37% | 5 | Dec 11, 2025 | |
| CATX Perspective Therapeutics | Assumes: Buy | $8 → $12 | $4.22 | +184.36% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $23 → $30 | $15.53 | +93.17% | 12 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $12.31 | +135.58% | 10 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $4.42 | +148.87% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $98.06 | +42.77% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $2.30 | +291.30% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $10 | $4.50 | +122.22% | 4 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $21.30 | +139.48% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $109.48 | +27.88% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $45 → $50 | $42.36 | +18.04% | 11 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $21.47 | +21.10% | 16 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $3.96 | +102.02% | 12 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $5 | $1.55 | +222.58% | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $182 → $172 | $189.15 | -9.07% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $113 → $38 | $69.11 | -45.74% | 14 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $6.70 | +79.10% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $5.29 | +164.65% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $23.31 | -22.78% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $1.11 | +4,224.32% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $110 → $20 | $4.37 | +358.19% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $0.79 | +1,918.42% | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $13.95 | +1,190.32% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $0.70 | +11,252.35% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $0.18 | +16,945.45% | 3 | Jun 2, 2020 |
BeOne Medicines AG
Feb 27, 2026
Maintains: Buy
Price Target: $400 → $412
Current: $276.95
Upside: +48.76%
Gilead Sciences
Feb 11, 2026
Maintains: Buy
Price Target: $145 → $152
Current: $136.88
Upside: +11.05%
CG Oncology
Feb 10, 2026
Maintains: Buy
Price Target: $66 → $75
Current: $66.67
Upside: +12.49%
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Buy
Price Target: $820 → $818
Current: $756.73
Upside: +8.10%
Viridian Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $41 → $40
Current: $28.20
Upside: +41.84%
Amgen
Jan 8, 2026
Maintains: Hold
Price Target: $318 → $319
Current: $353.16
Upside: -9.67%
IDEAYA Biosciences
Jan 6, 2026
Maintains: Buy
Price Target: $59 → $60
Current: $32.09
Upside: +86.97%
Agios Pharmaceuticals
Dec 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $29.95
Upside: +26.88%
Fulcrum Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $14 → $18
Current: $6.94
Upside: +159.37%
Perspective Therapeutics
Nov 24, 2025
Assumes: Buy
Price Target: $8 → $12
Current: $4.22
Upside: +184.36%
Nov 24, 2025
Assumes: Buy
Price Target: $23 → $30
Current: $15.53
Upside: +93.17%
Nov 24, 2025
Initiates: Buy
Price Target: $29
Current: $12.31
Upside: +135.58%
Nov 24, 2025
Initiates: Buy
Price Target: $11
Current: $4.42
Upside: +148.87%
Nov 24, 2025
Initiates: Buy
Price Target: $140
Current: $98.06
Upside: +42.77%
Nov 24, 2025
Initiates: Buy
Price Target: $9
Current: $2.30
Upside: +291.30%
Nov 24, 2025
Initiates: Hold
Price Target: $10
Current: $4.50
Upside: +122.22%
Nov 24, 2025
Initiates: Buy
Price Target: $51
Current: $21.30
Upside: +139.48%
Nov 24, 2025
Initiates: Buy
Price Target: $140
Current: $109.48
Upside: +27.88%
Jul 8, 2025
Downgrades: Sector Perform
Price Target: $45 → $50
Current: $42.36
Upside: +18.04%
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $21.47
Upside: +21.10%
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $3.96
Upside: +102.02%
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $1.55
Upside: +222.58%
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $189.15
Upside: -9.07%
Apr 16, 2025
Maintains: Sector Perform
Price Target: $113 → $38
Current: $69.11
Upside: -45.74%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $6.70
Upside: +79.10%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $5.29
Upside: +164.65%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $23.31
Upside: -22.78%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $1.11
Upside: +4,224.32%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $110 → $20
Current: $4.37
Upside: +358.19%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $0.79
Upside: +1,918.42%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $13.95
Upside: +1,190.32%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $0.70
Upside: +11,252.35%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $0.18
Upside: +16,945.45%